Compass GIST
21 Dec 2020
Trial Summary
An International, Multicenter, Open-label, Randomized, Phase 3 Study of Avapritinib vs Sunitinib in Patients with Genomically Selected Gastrointestinal Stromal Tumor (GIST).
Acronym:
BLU-285-1304
ACTRN/NCT /ethics:
–
Scientific title:
An International, Multicenter, Open-label, Randomized, Phase 3 Study of Avapritinib vs Sunitinib in Patients with Genomically Selected Gastrointestinal Stromal Tumor (GIST)
Sponsor / Cooperative group:
–
Trial & Patient Characteristics
| Cancer Type | Bowel and Colon, Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | - |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Dr Amitesh Roy |
| Recruitment Status | Not Yet Recruiting |